Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H1 2017’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)

– The report reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics and enlists all their major and minor projects

– The report assesses Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corp

CTI BioPharma Corp

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Incyte Corp

Italfarmaco SpA

JW Pharmaceutical Corp

MedImmune LLC

MEI Pharma Inc

Merck & Co Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Promedior Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development

Celgene Corp

CTI BioPharma Corp

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc

Incyte Corp

Italfarmaco SpA

JW Pharmaceutical Corp

MedImmune LLC

MEI Pharma Inc

Merck & Co Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Promedior Inc

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles

buparlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWP-291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glasdegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idelalisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LCL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pomalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sonidegib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones

Featured News & Press Releases

Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Celgene Corp, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by CTI BioPharma Corp, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Gilead Sciences Inc, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Incyte Corp, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Italfarmaco SpA, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by JW Pharmaceutical Corp, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MedImmune LLC, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MEI Pharma Inc, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Merck & Co Inc, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Novartis AG, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Pfizer Inc, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Promedior Inc, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Dormant Projects, H1 2017

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports